Annovis Bio (ANVS) Price & Analysis

Compare

654 Followers

ANVS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.11 - $10.54

Previous CloseN/A

Volume368.97K

Average Volume (3M)217.52K

Market Cap

$45.21M

Enterprise Value$25.15M

Total Cash (Recent Filing)$17.13B

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.81

Next Earnings

Nov 05, 2025

EPS Estimate

-0.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding19,486,230

10 Day Avg. Volume179,646

30 Day Avg. Volume217,516

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)6.58

Price to Sales (P/S)0.00

P/FCF Ratio>-0.01

Enterprise Value/Market Cap0.56

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.06

Forecast

1Y Price Target

$9.00

Price Target Upside287.93% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe pivotal Phase 3 study for buntanetap is ongoing and enrolling, with over 400 patients screened and 38 randomized to buntanetap or placebo.

Drug DevelopmentThe new crystalline form of buntanetap has improved solid-stage stability and comparable PK properties to the original, with bioequivalence demonstrated via animal studies.

Intellectual PropertyAnnovis announced the completion of patent transfer to the crystalline form of buntanetap, extending the IP estate around both forms of the drug to 2046.

Bears Say

Financial PerformanceAnnovis reported 2Q25 results with a net loss of ($6.2M) and ended the period with $17.1M in cash on the balance sheet.

Operational RisksRisks include failure to initiate trials in a timely manner, negative clinical data for buntanetap, inability to establish partnerships to commercialize buntanetap, failure to secure approval, slower-than-anticipated market uptake, and possible medium-term dilution risk.

Regulatory ApprovalReducing the 12-month price target to $10 from $12 reflects a lengthier time to potential approval of buntanetap.

Annovis Bio News

Annovis Bio announces publication of new article in Biomolecules on buntanetap

Annovis Bio (ANVS) announced the publication of a new article in a peer-reviewed journal Biomolecules, which describes the...

3d ago

ANVS

Annovis Bio price target lowered to $10 from $12 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Annovis Bio (ANVS) to $10 from $12 and keeps a...

16d ago

ANVS

Annovis Bio’s Promising Alzheimer’s Study: What Investors Need to Know

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Annovis Bio Inc. is conducting a...

12d ago

ANVS

Annovis Bio Reports Q2 2025 Progress and Financials

Annovis Bio Inc ( ($ANVS) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

ANVS

Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Study Overview: Annovis Bio Inc. is...

1M ago

ANVS

Annovis Bio’s Strategic Advancements and Phase 3 Study Progress Support Buy Rating

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Annovis Bio, with...

1M ago

ANVS

Annovis Bio completes full patent transfer to crystal buntanetap

Annovis Bio (ANVS) announced that all Company’s patents have been successfully transferred from the original form of buntanetap...

1M ago

ANVS

Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Annovis Bio Inc. is conducting a...

2M ago

ANVS

Annovis Bio Inc. Advances Alzheimer’s Treatment with Buntanetap Study

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Study Overview: Annovis Bio Inc. is...

2M ago

ANVS

Annovis Bio’s Alzheimer’s Study: A Potential Game-Changer for Investors?

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Annovis Bio Inc. is conducting a...

3M ago

ANVS

Annovis Bio’s Promising Alzheimer’s Study: A Potential Game Changer?

Annovis Bio Inc (($ANVS)) announced an update on their ongoing clinical study. Annovis Bio Inc. is conducting a...

3M ago

ANVS

Annovis Bio rises 16.3%

Annovis Bio (ANVS) is up 16.3%, or 43c to $3.07. Published first on TheFly – the ultimate source...

3M ago

ANVS

Annovis Bio Approves Board Elections and Auditor Appointment

An update from Annovis Bio ( ($ANVS) ) is now available. On June 17, 2025, Annovis Bio, Inc....

3M ago

ANVS

Annovis Bio’s NYSE Compliance Plan Accepted

Annovis Bio ( ($ANVS) ) has issued an announcement. On June 19, 2025, Annovis Bio announced that the...

3M ago

ANVS

ANVS FAQ

What was Annovis Bio’s price range in the past 12 months?

Annovis Bio lowest stock price was $1.11 and its highest was $10.54 in the past 12 months.

What is Annovis Bio’s market cap?

Annovis Bio’s market cap is $45.21M.

When is Annovis Bio’s upcoming earnings report date?

Annovis Bio’s upcoming earnings report date is Nov 05, 2025 which is in 47 days.

How were Annovis Bio’s earnings last quarter?

Annovis Bio released its earnings results on Aug 12, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.402 by $0.082.

Is Annovis Bio overvalued?

According to Wall Street analysts Annovis Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Annovis Bio pay dividends?

Annovis Bio does not currently pay dividends.

What is Annovis Bio’s EPS estimate?

Annovis Bio’s EPS estimate is -0.28.

How many shares outstanding does Annovis Bio have?

Annovis Bio has 19,486,230 shares outstanding.

What happened to Annovis Bio’s price movement after its last earnings report?

Annovis Bio reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.402. Following the earnings report the stock price went down -2.527%.

Which hedge fund is a major shareholder of Annovis Bio?

Currently, no hedge funds are holding shares in ANVS

Annovis Bio Stock Smart Score

Underperform

Fundamentals

Return on Equity

-365.03%

Trailing 12-Months

Asset Growth

325.14%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Annovis Bio

Annovis Bio (ANVS) is a clinical-stage pharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company is primarily engaged in the research and development of drugs aimed at treating conditions such as Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative disorders. Annovis Bio is committed to creating solutions that can halt or reverse the progression of these debilitating diseases by targeting the underlying biological pathways involved in neurodegeneration.

Annovis Bio (ANVS) Earnings & Revenues

Historic Earnings Reports

ANVS Stock 12 Month Forecast

Average Price Target

$9.00

▲(287.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.33,2.92,3.51,4.1,4.6899999999999995,5.279999999999999,5.87,6.46,7.05,7.64,8.23,8.82,9.41,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.33,2.8430769230769233,3.3561538461538465,3.8692307692307693,4.382307692307693,4.895384615384616,5.408461538461538,5.921538461538462,6.434615384615385,6.947692307692308,7.460769230769231,7.9738461538461545,8.486923076923077,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.33,2.766153846153846,3.2023076923076923,3.638461538461539,4.0746153846153845,4.510769230769231,4.946923076923078,5.383076923076923,5.819230769230769,6.2553846153846155,6.691538461538462,7.127692307692308,7.563846153846154,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.09,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.46,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.87,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.83,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.64,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >